Detalhe da pesquisa
1.
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lancet Oncol
; 22(12): 1740-1751, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34793719
2.
Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.
Clin Cancer Res
; 18(2): 568-76, 2012 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22090362
3.
Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer.
Invest New Drugs
; 26(5): 483-8, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18425418
4.
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
Blood
; 111(3): 1060-6, 2008 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17962510
5.
Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants.
Blood
; 103(1): 347-52, 2004 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12969970